123 related articles for article (PubMed ID: 38538281)
21. Interferon-γ-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines.
Niewerth D; Kaspers GJ; Assaraf YG; van Meerloo J; Kirk CJ; Anderl J; Blank JL; van de Ven PM; Zweegman S; Jansen G; Cloos J
J Hematol Oncol; 2014 Jan; 7():7. PubMed ID: 24418325
[TBL] [Abstract][Full Text] [Related]
22. Exocytosis of polyubiquitinated proteins in bortezomib-resistant leukemia cells: a role for MARCKS in acquired resistance to proteasome inhibitors.
Franke NE; Kaspers GL; Assaraf YG; van Meerloo J; Niewerth D; Kessler FL; Poddighe PJ; Kole J; Smeets SJ; Ylstra B; Bi C; Chng WJ; Horton TM; Menezes RX; Musters RJ; Zweegman S; Jansen G; Cloos J
Oncotarget; 2016 Nov; 7(46):74779-74796. PubMed ID: 27542283
[TBL] [Abstract][Full Text] [Related]
23. Zinc finger E-box binding factor 1 plays a central role in regulating Epstein-Barr virus (EBV) latent-lytic switch and acts as a therapeutic target in EBV-associated gastric cancer.
Zhao J; Jin H; Cheung KF; Tong JH; Zhang S; Go MY; Tian L; Kang W; Leung PP; Zeng Z; Li X; To KF; Sung JJ; Yu J
Cancer; 2012 Feb; 118(4):924-36. PubMed ID: 21717425
[TBL] [Abstract][Full Text] [Related]
24. The transcription factor ZEB1 mediates the progression of epithelial ovarian cancer by promoting the transcription of CircANKRD17.
Cai W; Zhang Q
J Biochem Mol Toxicol; 2022 Aug; 36(8):e23086. PubMed ID: 35521974
[TBL] [Abstract][Full Text] [Related]
25. Profound activity of the anti-cancer drug bortezomib against Echinococcus multilocularis metacestodes identifies the proteasome as a novel drug target for cestodes.
Stadelmann B; Aeschbacher D; Huber C; Spiliotis M; Müller J; Hemphill A
PLoS Negl Trop Dis; 2014 Dec; 8(12):e3352. PubMed ID: 25474446
[TBL] [Abstract][Full Text] [Related]
26. miR-128 modulates chemosensitivity and invasion of prostate cancer cells through targeting ZEB1.
Sun X; Li Y; Yu J; Pei H; Luo P; Zhang J
Jpn J Clin Oncol; 2015 May; 45(5):474-82. PubMed ID: 25921099
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance.
Kim A; Seong KM; Kang HJ; Park S; Lee SS
Oncotarget; 2015 Nov; 6(35):38225-38. PubMed ID: 26517678
[TBL] [Abstract][Full Text] [Related]
28. Characterization of bortezomib-adapted I-45 mesothelioma cells.
Zhang L; Littlejohn JE; Cui Y; Cao X; Peddaboina C; Smythe WR
Mol Cancer; 2010 May; 9():110. PubMed ID: 20482802
[TBL] [Abstract][Full Text] [Related]
29. Proteasome inhibitor-resistant cells cause EMT-induction via suppression of E-cadherin by miR-200 and ZEB1.
Asakura T; Yamaguchi N; Ohkawa K; Yoshida K
Int J Oncol; 2015 May; 46(5):2251-60. PubMed ID: 25738863
[TBL] [Abstract][Full Text] [Related]
30. Deubiquitinase OTUB2 promotes intrahepatic cholangiocarcinoma progression by stabilizing the CTNNB1-ZEB1 axis.
Wang J; Dong Y; Wei Z; Zhang Y; Wu N; Zhang C; Zhang Y; Zi R; Hao J; Liang H; Chen J
Exp Cell Res; 2023 Apr; 425(1):113537. PubMed ID: 36858343
[TBL] [Abstract][Full Text] [Related]
31. ZEB1 transcriptionally regulated carbonic anhydrase 9 mediates the chemoresistance of tongue cancer via maintaining intracellular pH.
Zheng G; Peng C; Jia X; Gu Y; Zhang Z; Deng Y; Wang C; Li N; Yin J; Liu X; Lu M; Tang H; He Z
Mol Cancer; 2015 Apr; 14():84. PubMed ID: 25890268
[TBL] [Abstract][Full Text] [Related]
32. Bortezomib-resistance is associated with increased levels of proteasome subunits and apoptosis-avoidance.
Wu YX; Yang JH; Saitsu H
Oncotarget; 2016 Nov; 7(47):77622-77634. PubMed ID: 27769058
[TBL] [Abstract][Full Text] [Related]
33. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
[No Abstract] [Full Text] [Related]
34. Endothelin-1 (ET-1) induces resistance to bortezomib in human multiple myeloma cells via a pathway involving the ETB receptor and upregulation of proteasomal activity.
Vaiou M; Pangou E; Liakos P; Sakellaridis N; Vassilopoulos G; Dimas K; Papandreou C
J Cancer Res Clin Oncol; 2016 Oct; 142(10):2141-58. PubMed ID: 27530445
[TBL] [Abstract][Full Text] [Related]
35. Notch1 is overexpressed in human intrahepatic cholangiocarcinoma and is associated with its proliferation, invasiveness and sensitivity to 5-fluorouracil in vitro.
Wu WR; Zhang R; Shi XD; Zhu MS; Xu LB; Zeng H; Liu C
Oncol Rep; 2014 Jun; 31(6):2515-24. PubMed ID: 24700253
[TBL] [Abstract][Full Text] [Related]
36. Combinations of proteasome inhibitors with obatoclax are effective for small cell lung cancer.
Yin YP; Shi WH; Deng K; Liu XL; Li H; Lv XT; Lui VWY; Ding C; Hong B; Lin WC
Acta Pharmacol Sin; 2021 Aug; 42(8):1298-1310. PubMed ID: 33139838
[TBL] [Abstract][Full Text] [Related]
37. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system.
Dou QP; Zonder JA
Curr Cancer Drug Targets; 2014; 14(6):517-36. PubMed ID: 25092212
[TBL] [Abstract][Full Text] [Related]
38. CSTF2T up-regulates IGHG1 by binding to ZEB1 to promote melanoma cell proliferation, migration, and invasion.
Li Y; Yun X; Li J; Bai M
Tissue Cell; 2023 Apr; 81():102029. PubMed ID: 36736099
[TBL] [Abstract][Full Text] [Related]
39. DUT enhances drug resistance to proteasome inhibitors via promoting mitochondrial function in multiple myeloma.
Wang Y; Gao S; Chen L; Liu S; Ma J; Cao Z; Li Q
Carcinogenesis; 2022 Dec; 43(11):1030-1038. PubMed ID: 36426924
[TBL] [Abstract][Full Text] [Related]
40. Bortezomib Inhibits Lung Fibrosis and Fibroblast Activation without Proteasome Inhibition.
Penke LRK; Speth J; Wettlaufer S; Draijer C; Peters-Golden M
Am J Respir Cell Mol Biol; 2022 Jan; 66(1):23-37. PubMed ID: 34236953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
